Gene therapy for hemoglobinopathies: The state of the field and the future

Hematology/Oncology Clinics of North America

Volumn 28, Issue 2, 2014, Pages 199-216

  Chandrakasan, Shanmuganathan ^a   Malik, Punam ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

Author keywords

Gene therapy; Hemoglobinopathy; Sickle cell disease; Thalassemia

Indexed keywords

HEMOGLOBIN BETA CHAIN; HEMOGLOBIN F; HEMOGLOBIN GAMMA CHAIN; LENTIVIRUS VECTOR;

BETA THALASSEMIA; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); GENE CONTROL; GENE TECHNOLOGY; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETIC TRANSDUCTION; GENOME; GLOBIN GENE; HEMATOPOIETIC STEM CELL; HEMOGLOBINOPATHY; HUMAN; PLURIPOTENT STEM CELL; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; STEM CELL GENE THERAPY; TRANSCRIPTION INITIATION; BETA-THALASSEMIA; GENETICS; HEMOGLOBINOPATHIES; LENTIVIRINAE; PROCEDURES; TRENDS;

BETA-GLOBINS; BETA-THALASSEMIA; GAMMA-GLOBINS; GENETIC THERAPY; GENETIC VECTORS; HEMOGLOBINOPATHIES; HUMANS; LENTIVIRUS;

EID: 84896806692     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.12.003     Document Type: Review

References (79)

1. Modell B. Global epidemiology of haemoglobin disorders and derived service indicators 2008, 417-496. World Health Organization, London, UK.
2. Weatherall D.J. The thalassemias: disorders of globin synthesis. Williams hematology 2010, McGraw-Hill, United States. 8th edition. K. Kaushansky, M. Lichtman, E. Beutler (Eds.).
3. Musallam K.M., Cappellini M.D., Taher A.T. Iron overload in beta-thalassemia intermedia: an emerging concern. Curr Opin Hematol 2013, 20:187-192.
4. Olivieri N.F., Nathan D.G., MacMillan J.H., et al. Survival in medically treated patients with homozygous beta-thalassemia. NEngl J Med 1994, 331:574-578.
5. Platt O.S., Brambilla D.J., Rosse W.F., et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. NEngl J Med 1994, 330:1639-1644.
6. Shenoy S. Hematopoietic stem-cell transplantation for sickle cell disease: current evidence and opinions. Ther Adv Hematol 2013, 4:335-344.
7. Angelucci E. Hematopoietic stem cell transplantation in thalassemia. Hematology Am Soc Hematol Educ Program 2010, 2010:456-462.
8. Walters M.C., Patience M., Leisenring W., et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 2001, 7:665-673.
9. Mentzer W.C., Heller S., Pearle P.R., et al. Availability of related donors for bone marrow transplantation in sickle cell anemia. Am J Pediatr Hematol Oncol 1994, 16:27-29.
10. La Nasa G., Argiolu F., Giardini C., et al. Unrelated bone marrow transplantation for beta-thalassemia patients: the experience of the Italian Bone Marrow Transplant Group. Ann N Y Acad Sci 2005, 1054:186-195.
11. Goussetis E., Peristeri I., Kitra V., et al. HLA-matched sibling stem cell transplantation in children with beta-thalassemia with anti-thymocyte globulin as part of the preparative regimen: the Greek experience. Bone Marrow Transplant 2012, 47:1061-1066.
12. Fleischhauer K., Locatelli F., Zecca M., et al. Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus-graft direction. Blood 2006, 107:2984-2992.
13. La Nasa G., Giardini C., Argiolu F., et al. Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes. Blood 2002, 99:4350-4356.
14. Thompson A.L., Bridley A., Twohy E., et al. An educational symposium for patients with sickle cell disease and their families: results from surveys of knowledge and factors influencing decisions about hematopoietic stem cell transplant. Pediatr Blood Cancer 2013, 60:1946-1951.
15. Walters M.C., Patience M., Leisenring W., et al. Barriers to bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 1996, 2:100-104.
16. Sankaran V.G., Orkin S.H. The switch from fetal to adult hemoglobin. Cold Spring Harb Perspect Med 2013, 3:a011643.
17. Sankaran V.G. Targeted therapeutic strategies for fetal hemoglobin induction. Hematology Am Soc Hematol Educ Program 2011, 2011:459-465.
18. Musallam K.M., Taher A.T., Cappellini M.D., et al. Clinical experience with fetal hemoglobin induction therapy in patients with beta-thalassemia. Blood 2013, 121:2199-2212. [quiz: 372].
19. Voskaridou E., Christoulas D., Bilalis A., et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood 2010, 115:2354-2363.
20. Cone R.D., Weber-Benarous A., Baorto D., et al. Regulated expression of a complete human beta-globin gene encoded by a transmissible retrovirus vector. Mol Cell Biol 1987, 7:887-897.
21. Karlsson S., Papayannopoulou T., Schweiger S.G., et al. Retroviral-mediated transfer of genomic globin genes leads to regulated production of RNA and protein. Proc Natl Acad Sci USA 1987, 84:2411-2415.
22. Grosveld F., van Assendelft G.B., Greaves D.R., et al. Position-independent, high-level expression of the human beta-globin gene in transgenic mice. Cell 1987, 51:975-985.
23. Collis P., Antoniou M., Grosveld F. Definition of the minimal requirements within the human beta-globin gene and the dominant control region for high level expression. EMBO J 1990, 9:233-240.
24. Ellis J., Tan-Un K.C., Harper A., et al. Adominant chromatin-opening activity in 5' hypersensitive site 3 of the human beta-globin locus control region. EMBO J 1996, 15:562-568.
25. Jarman A.P., Wood W.G., Sharpe J.A., et al. Characterization of the major regulatory element upstream of the human alpha-globin gene cluster. Mol Cell Biol 1991, 11:4679-4689.
26. Cavazzana-Calvo M., Fischer A., Hacein-Bey-Abina S., et al. Gene therapy for primary immunodeficiencies: part 1. Curr Opin Immunol 2012, 24:580-584.
27. Hacein-Bey-Abina S., Garrigue A., Wang G.P., et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. JClin Invest 2008, 118:3132-3142.
28. Boztug K., Schmidt M., Schwarzer A., et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. NEngl J Med 2010, 363:1918-1927.
29. Stein S., Ott M.G., Schultze-Strasser S., et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010, 16:198-204.
30. Miyoshi H., Blomer U., Takahashi M., et al. Development of a self-inactivating lentivirus vector. JVirol 1998, 72:8150-8157.
31. Naldini L., Blomer U., Gage F.H., et al. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996, 93:11382-11388.
32. Hargrove P.W., Kepes S., Hanawa H., et al. Globin lentiviral vector insertions can perturb the expression of endogenous genes in beta-thalassemic hematopoietic cells. Mol Ther 2008, 16:525-533.
33. Arumugam P.I., Higashimoto T., Urbinati F., et al. Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region. Mol Ther 2009, 17:1929-1937.
34. Dzierzak E.A., Papayannopoulou T., Mulligan R.C. Lineage-specific expression of a human beta-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells. Nature 1988, 331:35-41.
35. Novak U., Harris E.A., Forrester W., et al. High-level beta-globin expression after retroviral transfer of locus activation region-containing human beta-globin gene derivatives into murine erythroleukemia cells. Proc Natl Acad Sci USA 1990, 87:3386-3390.
36. Plavec I., Papayannopoulou T., Maury C., et al. Ahuman beta-globin gene fused to the human beta-globin locus control region is expressed at high levels in erythroid cells of mice engrafted with retrovirus-transduced hematopoietic stem cells. Blood 1993, 81:1384-1392.
37. Chang J.C., Liu D., Kan Y.W. A36-base-pair core sequence of locus control region enhances retrovirally transferred human beta-globin gene expression. Proc Natl Acad Sci USA 1992, 89:3107-3110.
38. Leboulch P., Huang G.M., Humphries R.K., et al. Mutagenesis of retroviral vectors transducing human beta-globin gene and beta-globin locus control region derivatives results in stable transmission of an active transcriptional structure. EMBO J 1994, 13:3065-3076.
39. Sadelain M., Wang C.H., Antoniou M., et al. Generation of a high-titer retroviral vector capable of expressing high levels of the human beta-globin gene. Proc Natl Acad Sci USA 1995, 92:6728-6732.
40. Sun F.L., Elgin S.C. Putting boundaries on silence. Cell 1999, 99:459-462.
41. Chung J.H., Bell A.C., Felsenfeld G. Characterization of the chicken beta-globin insulator. Proc Natl Acad Sci USA 1997, 94:575-580.
42. Recillas-Targa F., Pikaart M.J., Burgess-Beusse B., et al. Position-effect protection and enhancer blocking by the chicken beta-globin insulator are separable activities. Proc Natl Acad Sci USA 2002, 99:6883-6888.
43. Arumugam P.I., Urbinati F., Velu C.S., et al. The 3' region of the chicken hypersensitive site-4 insulator has properties similar to its core and is required for full insulator activity. PloS one 2009, 4:e6995.
44. May C., Rivella S., Callegari J., et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature 2000, 406:82-86.
45. Rivella S., May C., Chadburn A., et al. Anovel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. Blood 2003, 101:2932-2939.
46. Persons D.A., Hargrove P.W., Allay E.R., et al. The degree of phenotypic correction of murine beta -thalassemia intermedia following lentiviral-mediated transfer of a human gamma-globin gene is influenced by chromosomal position effects and vector copy number. Blood 2003, 101:2175-2183.
47. Arumugam P.I., Scholes J., Perelman N., et al. Improved human beta-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (cHS4) insulator element. Mol Ther 2007, 15:1863-1871.
48. Lisowski L., Sadelain M. Locus control region elements HS1 and HS4 enhance the therapeutic efficacy of globin gene transfer in beta-thalassemic mice. Blood 2007, 110:4175-4178.
49. Puthenveetil G., Scholes J., Carbonell D., et al. Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector. Blood 2004, 104:3445-3453.
50. Pawliuk R., Westerman K.A., Fabry M.E., et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 2001, 294:2368-2371.
51. Persons D.A., Allay E.R., Sabatino D.E., et al. Functional requirements for phenotypic correction of murine beta-thalassemia: implications for human gene therapy. Blood 2001, 97:3275-3282.
52. Cavazzana-Calvo M., Payen E., Negre O., et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010, 467:318-322.
53. Payen E., Leboulch P. Advances in stem cell transplantation and gene therapy in the beta-hemoglobinopathies. Hematology Am Soc Hematol Educ Program 2012, 2012:276-283.
54. Boulad F. Gene therapy for hemoglobinopathies BMT tandem meeting. Salt Lake City, February 13-17, 2013.
55. Levasseur D.N., Ryan T.M., Reilly M.P., et al. Arecombinant human hemoglobin with anti-sickling properties greater than fetal hemoglobin. JBiol Chem 2004, 279:27518-27524.
56. Levasseur D.N., Ryan T.M., Pawlik K.M., et al. Correction of a mouse model of sickle cell disease: lentiviral/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic stem cells. Blood 2003, 102:4312-4319.
57. Romero Z., Urbinati F., Geiger S., et al. Beta-globin gene transfer to human bone marrow for sickle cell disease. JClin Invest 2013, 123(8):3317-3330.
58. Pestina T.I., Hargrove P.W., Jay D., et al. Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin. Mol Ther 2009, 17:245-252.
59. Perumbeti A., Higashimoto T., Urbinati F., et al. Anovel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction. Blood 2009, 114:1174-1185.
60. Taher A.T., Otrock Z.K., Uthman I., et al. Thalassemia and hypercoagulability. Blood Rev 2008, 22:283-292.
61. Adler B.K., Salzman D.E., Carabasi M.H., et al. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood 2001, 97:3313-3314.
62. Yannaki E., Papayannopoulou T., Jonlin E., et al. Hematopoietic stem cell mobilization for gene therapy of adult patients with severe beta-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects. Mol Ther 2012, 20:230-238.
63. Yannaki E., Karponi G., Zervou F., et al. Hematopoietic stem cell mobilization for gene therapy: superior mobilization by the combination of plerixafor plus GCSF in patients with thalassemia major. Hum Gene Ther 2013, 24(10):852-860.
64. Zhao H., Pestina T.I., Nasimuzzaman M., et al. Amelioration of murine beta-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both gamma-globin and the MGMT drug-resistance gene. Blood 2009, 113:5747-5756.
65. Morianos I., Siapati E.K., Pongas G., et al. Comparative analysis of FV vectors with human alpha- or beta-globin gene regulatory elements for the correction of beta-thalassemia. Gene Ther 2012, 19:303-311.
66. Zhou D., Liu K., Sun C.W., et al. KLF1 regulates BCL11A expression and gamma- to beta-globin gene switching. Nat Genet 2010, 42:742-744.
67. Sankaran V.G., Menne T.F., Xu J., et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 2008, 322:1839-1842.
68. Xu J., Peng C., Sankaran V.G., et al. Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. Science 2011, 334:993-996.
69. Wilber A., Tschulena U., Hargrove P.W., et al. Azinc-finger transcriptional activator designed to interact with the gamma-globin gene promoters enhances fetal hemoglobin production in primary human adult erythroblasts. Blood 2010, 115:3033-3041.
70. Takahashi K., Tanabe K., Ohnuki M., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
71. Park I.H., Zhao R., West J.A., et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008, 451:141-146.
72. Papapetrou E.P., Lee G., Malani N., et al. Genomic safe harbors permit high beta-globin transgene expression in thalassemia induced pluripotent stem cells. Nat Biotechnol 2011, 29:73-78.
73. Urnov F.D., Miller J.C., Lee Y.L., et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005, 435:646-651.
74. Bedell V.M., Wang Y., Campbell J.M., et al. Invivo genome editing using a high-efficiency TALEN system. Nature 2012, 491:114-118.
75. Cho S.W., Kim S., Kim J.M., et al. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 2013, 31:230-232.
76. Chang C.J., Bouhassira E.E. Zinc-finger nuclease-mediated correction of alpha-thalassemia in iPS cells. Blood 2012, 120:3906-3914.
77. Sebastiano V., Maeder M.L., Angstman J.F., et al. In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases. Stem Cells 2011, 29:1717-1726.
78. Joung J.K., Sander J.D. TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol 2013, 14:49-55.
79. Sun N., Zhao H. Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs. Biotechnol Bioeng 2013, [Epub ahead of print].